⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702108 | 0.88 | CYP1A2 (0.43) | — | |
| SCHEMBL14659291 | 0.81 | SIGMAR1 (0.35) | — | |
| SCHEMBL15227572 | 0.80 | — | — | |
| SCHEMBL6177812 | 0.78 | — | — | |
| SCHEMBL3489809 | 0.75 | — | — | |
| SCHEMBL13619710 | 0.74 | — | — | |
| SCHEMBL456220 | 0.74 | — | — | |
| SCHEMBL5215899 | 0.73 | CYP1A2 (0.48) | — | |
| SCHEMBL131688 | 0.72 | — | — | |
| SCHEMBL15226795 | 0.70 | CYP1A2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |